衛光生物(002880.SZ):擬投資衛光生物智能產業基地項目
格隆匯7月18日丨衛光生物(002880.SZ)公佈,第四屆董事會第一次會議,審議通過了《關於投資衛光生物智能產業基地項目的議案》。本項目建設選址於深圳市光明區,光明區地處深圳市西北部,東至觀瀾、西接鬆崗、南抵石巖、北與東莞市接壤。本項目建設內容主要爲建設宿舍樓、多棟廠房、綜合倉庫、乙醇回收站、危化品庫、危廢品庫、乙醇地罐區和污水站房,滿足血液製品生產企業運營需求;二期預留高層廠房建設空間,打造現代化智能產業基地,滿足公司生產經營的需要;設計產能爲年處理血漿1,200噸。
本項目總投資230,794.66萬元,包括新增建設投資225,619.97萬元,利舊投資1,356.66萬元,貸款利息3,818.03萬元。資金來源爲企業自籌。如本項目全部或部分作爲募集資金投資項目,需全額或部分使用募集資金的,公司將嚴格按照募集資金投資項目及募集資金監管的有關規定執行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.